RioMSK-001 is under clinical development by Rion and currently in Phase I for Osteoarthritis. According to GlobalData, Phase I drugs for Osteoarthritis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RioMSK-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RioMSK-001 overview
RioMSK-001 is under development for the treatment of osteoarthritis. The drug candidate comprises of exosomes. It is administered through intraarticular route and is being developed based on Purified Exosome Product (PEP) technology.
Rion overview
Rion is a clinical-stage regenerative medicine company. It develops purified exosome product (PEP), a biologic platform that optimizes the therapeutic power of exosomes for regenerative medicine. The company’s pipeline products in advanced wound care therapeutic area include RioDerm001, RioDerm002, RioDerm003 and RioDerm004; musculoskeletal therapeutic area comprise RioMSK001, RioMSK002; cardiovascular area include RioCard001; Pulmonary therapeutic area comprise RioPulm001; exosome drug delivery area include Cypher001, Cypher002 and eCypher001. Rion is headquartered in Rochester, Minnesota, the US.
For a complete picture of RioMSK-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
